Cargando…
Safety and Efficacy of Intracavernosal Injections of AbobotulinumtoxinA (Dysport(®)) as Add on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 for Erectile Dysfunction—Case Studies
Erectile dysfunction (ED) is a highly prevalent condition with a variety of possible risk factors and/or etiologies. Despite significant advances regarding ED pharmacological management, there are still insufficient responders to existing pharmacological treatments e.g., approximately 30% of patient...
Autores principales: | Giuliano, Francois, Joussain, Charles, Denys, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563248/ https://www.ncbi.nlm.nih.gov/pubmed/31117236 http://dx.doi.org/10.3390/toxins11050283 |
Ejemplares similares
-
Introduction to the Supplement: A Review of AbobotulinumtoxinA (Dysport)
por: Dover, Jeffrey S.
Publicado: (2017) -
Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin(®)) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series
por: Giuliano, Francois, et al.
Publicado: (2022) -
Safety and Effectiveness of Repeated Botulinum Toxin A Intracavernosal Injections in Men with Erectile Dysfunction Unresponsive to Approved Pharmacological Treatments: Real-World Observational Data
por: Giuliano, François, et al.
Publicado: (2023) -
Early AbobotulinumtoxinA (Dysport(®)) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study
por: Rosales, Raymond L, et al.
Publicado: (2018) -
The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury
por: Esquenazi, Alberto, et al.
Publicado: (2020)